MAPK3 and type 2 diabetes mellitus: The levels of p-ERK1/2 and p-JNK were both increased, and p-GSK3b (Ser9), which is the inactivated site of GSK-3b, was decreased in T2DM group, while p-ERK1/2 and p-JNK were decreased after Zonisamide treatment.